Product image of Oxaviatin (Oxaliplatin) supplied by GNH India

Oxaviatin

Active Ingredient:
Oxaliplatin
Origin:
EU

Oxaviatin (Oxaliplatin)

Oxaliplatin, the active ingredient in Oxaviatin, is a platinum-based chemotherapy agent presented as a 100 mg powder for intravenous infusion use. It treats colorectal cancer and other solid tumours in adult patients. GNH India supplies Oxaviatin as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH India supplies Oxaviatin as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Manufacturer / TM Owner

Vianex S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Oxaviatin is a platinum‑based chemotherapy drug used in the treatment of cancers that arise from the gastrointestinal tract and related pathways.

  • Colorectal cancer: improves survival by inhibiting tumour cell replication.
  • Gastric cancer: used in combination regimens to reduce tumour burden.
  • Pancreatic cancer: part of multi‑drug protocols to control disease progression.

How It Works

  • Oxaliplatin forms reactive platinum complexes that bind to DNA, creating intra‑ and interstrand cross‑links that disrupt DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing cancer cells while sparing most normal tissues.

Side Effects

Oxaviatin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects

  • Nausea and vomiting: frequent during and after infusion.
  • Peripheral neuropathy: tingling or numbness in hands and feet.
  • Diarrhoea: may be mild to moderate.
  • Fatigue: general tiredness and reduced stamina.
  • Myelosuppression: lowered blood cell counts.
  • Elevated liver enzymes: mild increase in hepatic enzymes.

Serious or Rare Side Effects

  • Severe allergic reactions: anaphylaxis or infusion‑related hypersensitivity.
  • Acute pulmonary toxicity: difficulty breathing or reduced oxygenation.
  • Severe neutropenia: markedly low neutrophil count increasing infection risk.
  • Thrombocytopenia: low platelet count leading to bleeding tendencies.
  • Renal impairment: reduced kidney function during treatment.
  • Cardiac arrhythmias: irregular heart rhythms observed in rare cases.

Precautions & Warnings

Before initiating Oxaviatin therapy, clinicians should assess patient suitability and monitor for potential complications.

  • Renal function: evaluate creatinine clearance before each cycle.
  • Hepatic function: check liver enzymes and bilirubin levels.
  • Neuropathy risk: assess baseline peripheral nerve status.
  • Hematologic status: monitor complete blood count regularly.
  • Concomitant ototoxic drugs: avoid or adjust dosing when possible.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Oxaviatin can interact with several medicines, altering efficacy or safety; careful review of the patient’s medication list is essential.

Major Interactions (Avoid)

  • Nephrotoxic agents: concurrent use may worsen kidney injury.
  • Highly protein‑bound drugs: may displace oxaliplatin, increasing free drug levels.

Moderate Interactions (Monitor Closely)

  • Antiemetics: dose adjustments may be needed to control nausea.
  • Anticoagulants: monitor coagulation parameters for bleeding risk.
  • CYP450 inducers: may reduce oxaliplatin exposure.
  • Radiotherapy: combined use can increase neurotoxicity.
  • Herbal supplements: potential unknown effects on drug metabolism.

Frequently Asked Questions

Oxaviatin contains oxaliplatin, a platinum‑based chemotherapy agent indicated for the treatment of colorectal cancer and, in combination regimens, for gastric and pancreatic cancers in adult patients. It is used as part of multi‑drug protocols to inhibit tumour growth.

Oxaliplatin forms platinum‑DNA adducts that create cross‑links within and between DNA strands. These cross‑links block DNA replication and transcription, leading to cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells.

The dosing regimen for Oxaviatin is determined by the prescribing oncologist based on the patient’s cancer type, stage, renal function and overall health. Clinicians calculate the dose per square metre of body‑surface area and adjust it according to treatment response and toxicity.

Oxaviatin is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Breastfeeding is not recommended while receiving treatment, as the drug may be excreted in milk and affect the infant.

To order Oxaviatin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Oxaviatin (oxaliplatin) differs from cisplatin and carboplatin in its side‑effect profile, notably causing less nephrotoxicity but more peripheral neuropathy. It is often preferred for colorectal cancer regimens, while cisplatin is commonly used for testicular, ovarian and head‑and‑neck cancers.

Oxaviatin should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. The product must be reconstituted with the appropriate diluent immediately before intravenous administration and used within the time frame specified in the label.

Oxaviatin is supplied as a sterile powder for intravenous infusion. After reconstitution, the solution is administered by a healthcare professional through a peripheral or central line, typically over a period of 2 hours, according to the prescribing protocol.

Serious risks include severe peripheral neuropathy, acute allergic reactions, significant myelosuppression leading to infection or bleeding, and rare pulmonary or cardiac toxicity. Patients should be monitored closely for these events throughout treatment.

Oxaviatin is contraindicated in patients with known hypersensitivity to oxaliplatin or other platinum compounds, in those with severe pre‑existing neuropathy, and in pregnant women. Caution is also advised for patients with compromised renal or hepatic function.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Oxaliplatin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT